NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121